BioPorto Past Earnings Performance
Past criteria checks 0/6
BioPorto's earnings have been declining at an average annual rate of -3.1%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 4.4% per year.
Key information
-3.1%
Earnings growth rate
15.1%
EPS growth rate
| Biotechs Industry Growth | 18.7% |
| Revenue growth rate | 4.4% |
| Return on equity | -129.1% |
| Net Margin | -166.2% |
| Next Earnings Update | 01 Aug 2024 |
Recent past performance updates
Recent updates
We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Dec 25
We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jun 28We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely
Feb 27Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
Oct 19We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate
Jun 15Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation
Oct 16Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth
May 28BioPorto A/S' (CPH:BIOPOR) Path To Profitability
Mar 01We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully
Jan 24A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration
Dec 20The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts
Nov 23
BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Nov 21Revenue & Expenses Breakdown
How BioPorto makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 32 | -54 | 51 | 26 |
| 31 Dec 23 | 31 | -56 | 55 | 25 |
| 30 Sep 23 | 33 | -70 | 61 | 26 |
| 30 Jun 23 | 30 | -78 | 63 | 32 |
| 31 Mar 23 | 31 | -75 | 65 | 33 |
| 31 Dec 22 | 29 | -76 | 63 | 35 |
| 30 Sep 22 | 27 | -68 | 58 | 36 |
| 30 Jun 22 | 27 | -62 | 56 | 33 |
| 31 Mar 22 | 25 | -59 | 51 | 30 |
| 31 Dec 21 | 24 | -57 | 50 | 30 |
| 30 Sep 21 | 25 | -54 | 48 | 27 |
| 30 Jun 21 | 24 | -60 | 48 | 29 |
| 31 Mar 21 | 25 | -62 | 48 | 31 |
| 31 Dec 20 | 23 | -62 | 49 | 28 |
| 30 Sep 20 | 22 | -64 | 45 | 30 |
| 30 Jun 20 | 24 | -68 | 54 | 29 |
| 31 Mar 20 | 25 | -69 | 59 | 25 |
| 31 Dec 19 | 27 | -70 | 62 | 25 |
| 30 Sep 19 | 29 | -61 | 63 | 22 |
| 30 Jun 19 | 28 | -51 | 55 | 16 |
| 31 Mar 19 | 27 | -43 | 47 | 17 |
| 31 Dec 18 | 26 | -38 | 41 | 19 |
| 30 Sep 18 | 24 | -38 | 37 | 22 |
| 30 Jun 18 | 25 | -36 | 34 | 25 |
| 31 Mar 18 | 24 | -35 | 33 | 24 |
| 31 Dec 17 | 25 | -32 | 33 | 22 |
| 30 Sep 17 | 25 | -29 | 57 | 25 |
| 30 Jun 17 | 23 | -27 | 49 | 18 |
| 31 Mar 17 | 21 | -26 | 40 | 14 |
| 31 Dec 16 | 21 | -23 | 31 | 10 |
| 30 Sep 16 | 20 | -21 | 18 | 10 |
| 30 Jun 16 | 20 | -16 | 18 | 10 |
| 31 Mar 16 | 21 | -12 | 18 | 10 |
| 31 Dec 15 | 20 | -11 | 18 | 10 |
| 30 Sep 15 | 20 | -11 | 20 | 9 |
| 30 Jun 15 | 19 | -12 | 20 | 9 |
| 31 Mar 15 | 18 | -13 | 20 | 9 |
| 31 Dec 14 | 19 | -13 | 20 | 9 |
| 30 Sep 14 | 18 | -15 | 19 | 10 |
| 30 Jun 14 | 19 | -19 | 19 | 10 |
| 31 Mar 14 | 18 | -20 | 19 | 10 |
| 31 Dec 13 | 17 | -22 | 19 | 10 |
| 30 Sep 13 | 17 | -20 | 15 | 10 |
| 30 Jun 13 | 16 | -17 | 15 | 10 |
Quality Earnings: BIOPOR is currently unprofitable.
Growing Profit Margin: BIOPOR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOPOR is unprofitable, and losses have increased over the past 5 years at a rate of 3.1% per year.
Accelerating Growth: Unable to compare BIOPOR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOPOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: BIOPOR has a negative Return on Equity (-129.05%), as it is currently unprofitable.